Valuation: Capricor Therapeutics, Inc.

Market Cap 438M 399M 369M 334M 627M 40.89B 656M 4.46B 1.77B 22.1B 1.64B 1.61B 69.99B P/E 2026 *
-3.06x
P/E 2027 * -5.22x
Enterprise Value 438M 399M 369M 334M 627M 40.89B 656M 4.46B 1.77B 22.1B 1.64B 1.61B 69.99B EV / Sales 2026 *
33x
EV / Sales 2027 * 6.6x
Free-Float
89.1%
Yield 2026 *
-
Yield 2027 * -
1 day+5.51%
1 week-19.41%
Current month+20.38%
1 month+16.19%
3 months+12.36%
6 months-73.53%
Current year-73.39%
1 week 7.38
Extreme 7.38
9.49
1 month 5.67
Extreme 5.67
11.23
Current year 2.96
Extreme 2.96
36.82
1 year 2.96
Extreme 2.96
40.37
3 years 2.87
Extreme 2.87
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 2013-11-19
Director of Finance/CFO 40 2017-12-31
Chief Tech/Sci/R&D Officer - 2025-05-12
Director TitleAgeSince
Chairman 70 2013-10-31
Director/Board Member 68 2013-11-19
Director/Board Member 79 2013-11-19
Date Insider Type Main position Quantity % Market Cap. Importance
5/26/26 Free

CHIEF COMMERCIAL OFFICER

80,000 0.1383%
5/18/26 Exercice

Chief Financial Officer

6,000 0.0104%
5/13/26 Exercice

Chairman

7,874 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
+5.11%-19.41%+34.97%+158.59% 438M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.23%-2.66%+6.48%+89.70% 58.91B
-2.22%-2.04%+23.09%+82.64% 55.24B
-0.83%-4.79%+13.54%+111.09% 45.66B
-1.24%-6.24%+14.49%+21.08% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+4.32%-3.67%+137.51%+663.81% 34.48B
-0.40%+1.07%+78.08%+56.98% 32.5B
+1.87%+19.00%-27.78%+485.62% 31.69B
Average +0.26%-3.24%+35.23%+177.95% 40B
Weighted average by Cap. -0.63%-1.31%+33.29%+153.81%

Financials

2026 *2027 *
Net sales 13.26M 12.08M 11.18M 10.11M 18.97M 1.24B 19.86M 135M 53.61M 669M 49.73M 48.69M 2.12B 66.37M 60.47M 55.98M 50.64M 94.99M 6.2B 99.42M 677M 268M 3.35B 249M 244M 10.61B
Net income -145M -132M -122M -110M -207M -13.51B -217M -1.48B -585M -7.3B -543M -531M -23.13B -87.77M -79.97M -74.03M -66.96M -126M -8.2B -131M -895M -355M -4.43B -329M -322M -14.03B
Net Debt - -
Projected Income Statement - Annual - Capricor Therapeutics, Inc.
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
26-11-20 $8.065 +7.10% 4,452,111
26-11-19 $7.530 -6.23% 8,055,671
26-11-18 $8.030 -4.52% 8,383,545
26-11-17 $8.410 +1.33% 4,693,636
26-11-16 $8.300 -12.91% 3,919,851
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Capricor Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
7.530USD
Average target price
27.25USD
Spread / Average Target
+261.89%
  1. Stock Market
  2. Stocks
  3. CAPR Stock